Can-Fite says Piclidenoson study shows mobility, pain improvements in canine osteoarthritis

• Can-Fite BioPharma flagged a newly published, peer-reviewed article detailing previously reported positive findings for Piclidenoson in dogs with osteoarthritis.
• The study showed the oral drug improved mobility and reduced pain in affected dogs, with a safety profile that supported continued development.
• Results have already been presented, with the publication positioned as external validation for the program.
• Vetbiolix is running an advanced Phase 2 study in canine osteoarthritis under a licensing deal worth up to USD 325 million in upfront, milestone, and royalty payments.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Can Fite Biofpharma Ltd. published the original content used to generate this news brief on May 18, 2026, and is solely responsible for the information contained therein.